GTS Securities’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-10,466
Closed -$1.67M 1695
2025
Q4
$1.67M Buy
+10,466
New +$1.44M 0.06% 267
2025
Q2
Sell
-24,006
Closed -$1.46M 1451
2025
Q1
$1.46M Buy
24,006
+1,343
+6% +$114K 0.06% 249
2024
Q4
$2.04M Sell
22,663
-24,618
-52% -$2.9M 0.1% 160
2024
Q3
$6.09M Buy
47,281
+6,654
+16% +$868K 0.01% 767
2024
Q2
$4.61M Buy
40,627
+28,486
+235% +$3.05M 0.01% 911
2024
Q1
$1.61M Sell
12,141
-14,627
-55% -$1.91M ﹤0.01% 1623
2023
Q4
$3.26M Buy
26,768
+11,942
+81% +$914K 0.01% 1296
2023
Q3
$1.13M Buy
14,826
+1,878
+15% +$193K ﹤0.01% 1914
2023
Q2
$1.53M Buy
+12,948
New +$1.61M 0.05% 320

Other funds holding LABU

GTS Securities's LABU Position: Q1 2026 in Review

GTS Securities sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026, closing a stake of 10,466 shares — an estimated $1.67M sold.

GTS Securities first reported a position in LABU in Q2 2023 and held it in 9 quarters. The position peaked at $6.09M in Q3 2024. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • GTS Securities reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
  • GTS Securities sold 10,466 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $1.67M.
  • GTS Securities first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2023 and held it in 9 quarters.
  • GTS Securities's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $6.09M in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.